SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: BYR-174832 |   Information Technology

Historical data: 2017 - 2023

Forecast period: 2025 - 2031

Quantitative units: Revenue in USD million and CAGR from 2025 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Specific Antiviral Drugs For Covid-19 Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET

7.1 GLOBAL SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)

8.1 GLOBAL SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

8.2 GLOBAL SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

9.1 GLOBAL SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

9.2 GLOBAL SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

10.1 GLOBAL SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)

10.2 GLOBAL SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)

11.1 NORTH AMERICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

11.2 NORTH AMERICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

11.3 NORTH AMERICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

11.4 NORTH AMERICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

11.5 NORTH AMERICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

11.6 NORTH AMERICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

12.1 EUROPE SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

12.2 EUROPE SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

12.3 EUROPE SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

12.4 EUROPE SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

12.5 EUROPE SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

12.6 EUROPE SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

13.1 ASIA PACIFIC SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

13.2 ASIA PACIFIC SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

13.3 ASIA PACIFIC SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

13.4 ASIA PACIFIC SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

13.5 ASIA PACIFIC SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

13.6 ASIA PACIFIC SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

14.1 LATIN AMERICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>

14.2 LATIN AMERICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

14.3 LATIN AMERICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

14.4 LATIN AMERICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

14.5 LATIN AMERICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

14.6 LATIN AMERICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA SPECIFIC ANTIVIRAL DRUGS FOR COVID-19 MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>

16.1 Sanofi

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Novartis

16.3 Shanghai Zhongxisanwei

16.4 Teva

16.5 Zydus Cadila

16.6 Mylan

16.7 Apotex

16.8 Advanz Pharma

16.9 Sun Pharma

16.10 Kyung Poong

16.11 Ipca Laboratories

16.12 Hanlim Pharmaceutical

16.13 Bristol Laboratories

16.14 Bayer

16.15 Rising Pharmaceutical

16.16 Shanghai Pharma

16.17 Sichuan Sunny Hope

16.18 Guangzhou Baiyunshan Guanghua Pharmaceutical

16.19 CSPC Group

16.20 KPC Group

16.21 Jinghua Pharmaceutical Group

16.22 Zhongsheng Pharma

16.23 North China Pharmaceutical Group

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Segment by Type
Tablet
Injection



Segment by Application
Mild Symptom Patient
Critically Ill Patient

Companies

Sanofi
Novartis
Shanghai Zhongxisanwei
Teva
Zydus Cadila
Mylan
Apotex
Advanz Pharma
Sun Pharma
Kyung Poong
Ipca Laboratories
Hanlim Pharmaceutical
Bristol Laboratories
Bayer
Rising Pharmaceutical
Shanghai Pharma
Sichuan Sunny Hope
Guangzhou Baiyunshan Guanghua Pharmaceutical
CSPC Group
KPC Group
Jinghua Pharmaceutical Group
Zhongsheng Pharma
North China Pharmaceutical Group

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.